Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained...

Descripción completa

Detalles Bibliográficos
Autores principales: Landewé, Robert BM, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip E, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, Davies, Owen R, de Peyrecave, Natasha, Thomas, Karen, Gensler, Lianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://www.ncbi.nlm.nih.gov/pubmed/32381562
http://dx.doi.org/10.1136/annrheumdis-2019-216839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://www.ncbi.nlm.nih.gov/pubmed/32381562
http://dx.doi.org/10.1136/annrheumdis-2019-216839

Ejemplares similares